Origin of multifocal carcinomas of the bladder and upper urinary tract: Molecular analysis and clinical implications

International Journal of Urology

Volumn 12, Issue 8, 2005, Pages 709-716

  Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bladder cancer; Molecular genetics; Multifocality; Recurrence; Urothelial cancer

Indexed keywords

BCG VACCINE; DOXORUBICIN; EPIRUBICIN; PROTEIN P53;

BLADDER CARCINOMA; CANCER RECURRENCE; CARCINOGENIC ACTIVITY; CELL TRANSFORMATION; CLONE; GENE MUTATION; HUMAN; MOLECULAR GENETICS; MULTIPLE CANCER; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STEM CELL; URINARY TRACT CARCINOMA; X CHROMOSOME;

HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 28544432309     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2005.01155.x     Document Type: Review

References (67)

1. Kakizoe T, Tobisu K, Tanaka Y et al. Development of multiple transitional cell carcinomas in the urinary tract. Jpn J. Clin. Oncol. 1991; 21: 110-14.
2. Mufti GR, Singh M. Value of random mucosal biopsies in the management of superficial bladder cancer. Eur. Urol. 1992; 22: 288-93.
3. Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am. J. Surg. Pathol. 1999; 23: 443-7.
4. Harris AL, Neal DE. Bladder cancer - field versus clonal origin. N. Engl. J. Med. 1992; 326: 759-61.
5. Garcia SB, Park HS, Novelli M, Wright NA. Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets. J. Pathol. 1999; 187: 61-81.
6. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6: 963-8.
7. Scholes AG, Woolgar JA, Boyle MA et al. Synchronous oral carcinomas: independent or common clonal origin? Cancer Res. 1998; 58: 2003-6.
8. Sozzi G, Miozzo M, Pastorino U et al. Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. Cancer Res. 1995; 55: 135-40.
9. Bedi GC, Westra WH, Gabrielson E, Koch W, Sidransky D. Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res. 1996; 56: 2484-7.
10. Noguchi S, Aihara T, Koyama H, Motomura K, Inaji H, Imaoka S. Discrimination between multicentric and multifocal carcinomas of the breast through clonal analysis. Cancer 1994; 74: 872-7.
11. Abeln EC, Kuipers-Dijkshoorn NJ, Berns EM, Henzen-Logmans SC, Fleuren GJ, Cornelisse CJ. Molecular genetic evidence for unifocal origin of advanced epithelial ovarian cancer and for minor clonal divergence. Br. J. Cancer 1995; 72: 1330-6.
12. Larson AA, Liao SY, Stanbridge EJ, Cavenee WK, Hampton GM. Genetic alterations accumulate during cervical tumorigenesis and indicate a common origin for multifocal lesions. Cancer Res. 1997; 57: 4171-6.
13. Franklin WA, Gazdar AF, Haney J et al. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J. Clin. Invest. 1997; 100: 2133-7.
14. Hruban RH, van der Riet P, Erozan YS, Sidransky D. Brief report: molecular biology and the early detection of carcinoma of the bladder - the case of Hubert H. Humphrey. N. Engl. J. Med. 1994; 330: 1276-8.
15. Xu X, Stower MJ, Reid IN, Garner RC, Burns PA. Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers. Clin. Cancer Res. 1996; 2: 1795-800.
16. Takahashi T, Habuchi T, Kakehi Y et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res. 1998; 58: 5835-41.
17. Takahashi T, Habuchi T, Kakehi Y et al. Molecular diagnosis of metastatic origin in a patient with metachronous multiple cancers of the renal pelvis and bladder. Urology 2000; 56: 331.
18. Vriesema JL, Aben KK, Witjes JA, Kiemeney LA, Schalken JA. Superficial and metachronous invasive bladder carcinomas are clonally related. Int. J. Cancer 2001; 93: 699-702.
19. Kang CH, Yu TJ, Hsieh HH et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003; 98: 1620-6.
20. Matsui Y, Utsunomiya N, Ichioka K et al. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 2005; 65: 279-83.
21. Amar AD, Das S. Upper urinary tract transitional cell carcinoma in patients with bladder carcinoma and associated vesicoureteral reflux. J. Urol. 1985; 133: 468-71.
22. De Torres Mateos JA, Banus Gassol JM, Palou Redorta J, Morote Robles J. Vesicorenal reflux and upper urinary tract transitional cell carcinoma after transurethral resection of recurrent superficial bladder carcinoma. J. Urol. 1987; 138: 49-51.
23. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin bladder cancer. N. Engl. J. Med. 1992; 326: 737-40.
24. Lunec J, Challen C, Wright C, Mellon K, Neal DE. c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder. Lancet 1992; 339: 439-40.
25. Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 1993; 342: 1087-8.
26. Fadl-Elmula I, Gorunova L, Mandahl N et al. Cytogenetic monoclonality in multifocal uroepithelial carcinomas: evidence of intraluminal tumour seeding. Br. J. Cancer 1999; 81: 6-12.
27. Li M, Cannizzaro LA. Identical clonal origin of synchronous and metachronous low-grade, noninvasive papillary transitional cell carcinomas of the urinary tract. Hum. Pathol. 1999; 30: 1197-200.
28. Hartmann A, Rosner U, Schlake G et al. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab. Invest 2000; 80: 709-18.
29. Louhelainen J, Wijkstrom H, Hemminki K. Allelic losses demonstrate monoclonality of multifocal bladder tumors. Int. J. Cancer 2000; 87: 522-7.
30. Hafner C, Knuechel R, Zanardo L et al. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene 2001; 20: 4910-15.
31. Simon R, Eltze E, Schafer KL et al. Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. Cancer Res. 2001; 61: 355-62.
32. Hainaut P, Hernandez T, Robinson A et al. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. 1998; 26: 205-13.
33. Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang ZQ, Hainaut P. New approaches to understanding p53 gene tumor mutation spectra. Mutat. Res. 1999; 431: 199-209.
34. Goto K, Konomoto T, Hayashi K et al. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas. Mod. Pathol. 1997; 10: 428-37.
35. Yamamoto S, Tada M, Lee CC et al. p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry. Jpn J. Cancer Res. 2000; 91: 181-9.
36. Fujimoto K, Yamada Y, Okajima E et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res. 1992; 52: 1393-8.
37. Habuchi T, Takahashi R, Yamada H et al. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res. 1993; 53: 3795-9.
38. Weber JL, May PE. Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am. J. Hum. Genet. 1989; 44: 388-96.
39. Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D. Microsatellite alterations as clonal markers for the detection of human cancer. Proc. Natl. Acad. Sci. USA 1994; 91: 9871-5.
40. Mao L, Schoenberg MP, Scicchitano M et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996; 271: 659-62.
41. Steiner G, Schoenberg MP, Linn JF, Mao E, Sidransky D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat. Med. 1997; 3: 621-4.
42. Takahashi T, Kakehi Y, Mitsumori K et al. Distinct microsatellite alterations in upper urinary tract tumors and subsequent bladder tumors. J. Urol. 2001; 165: 672-7.
43. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res. 1994; 54: 531-8.
44. Hartmann A, Schlake G, Zaak D et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res. 2002; 62: 809-18.
45. Muto S, Horie S, Takahashi S, Tomita K, Kitamura T. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res. 2000; 60: 4021-5.
46. Habuchi T, Takahashi T, Kakinuma H et al. Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene 2001; 20: 531-7.
47. Miyake H, Hara I, Kamidono S, Eto H. Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns. J. Urol. 2004; 172: 1127-9.
48. Cianciulli AM, Leonardo C, Guadagni F et al. Genetic instability in superficial bladder cancer and adjacent mucosa: an interphase cytogenetic study. Hum. Pathol. 2003; 34: 214-21.
49. Stoehr R, Knuechel R, Boecker J et al. Histologic-genetic mapping by allele-specific PCR reveals intraurothelial spread of p53 mutant tumor clones. Lab. Invest. 2002; 82: 1553-61.
50. Seripa D, Parrella P, Gallucci M et al. Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine. Int. J. Cancer 2001; 95: 364-9.
51. van Rhijn BW, Lurkin I, Kirkels WJ, van der Kwast TH, Zwarthoff EC. Microsatellite analysis - DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial. Cancer 2001; 92: 768-75.
52. Sidransky D, Von Eschenbach A, Tsai YC et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991; 252: 706-9.
53. van Rhijn BW, Lurkin I, Chopin DK et al. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin. Cancer Res. 2003; 9: 257-63.
54. Conejo JR, Parra T, Cantero M et al. Detection of H-ras mutations in urine sediments by a mutant-enriched PCR technique. Clin. Chem. 1998; 44: 1570-2.
55. Matsumura Y, Hanbury D, Smith J, Tarin D. Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells. BMJ 1994; 308: 619-24.
56. Soloway MS, Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer 1980; 46: 1158-63.
57. See WA, Miller JS, Williams RD. Pathophysiology of transitional tumor cell adherence to sites of urothelial injury in rats: mechanisms mediating intravesical recurrence due to implantation. Cancer Res. 1989; 49: 5414-18.
58. Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J. Urol. 1993; 149: 749-52.
59. Ali-el-Dein B, Nabeeh A, el-Baz M, Shamaa S, Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br. J. Urol. 1997; 79: 731-5.
60. Okamura K, Ono Y, Kinukawa T et al. Randomized study of single early instillation of (2″R)-4′-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 2002; 94: 2363-8.
61. Rubben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G. Natural history and treatment of low and high risk superficial bladder tumors. J. Urol. 1988; 139: 283-5.
62. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 2000; 163: 1124-9.
63. Badalament RA, Herr HW, Wong GY et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J. Clin. Oncol. 1987; 5: 441-9.
64. Flamm J. Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer. Eur. Urol 1990; 17: 119-24.
65. Okamura K, Kinukawa T, Tsumura Y et al. A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncolology Group. Eur. Urol. 1998; 33: 285-8; discussion 289.
66. Kamat AM, Lamm DL. Chemoprevention of bladder cancer. Urol. Clin. North Am. 2002; 29: 157-68.
67. Lieberman R. Chemoprevention of superficial bladder cancer. Cancer Treat. Res. 2001; 106: 237-54.